Published in J Antimicrob Chemother on March 01, 1993
Modulation of release of proinflammatory bacterial compounds by antibacterials: potential impact on course of inflammation and outcome in sepsis and meningitis. Clin Microbiol Rev (2002) 1.61
Clinical relevance of antibiotic-induced endotoxin release. Antimicrob Agents Chemother (1994) 1.48
Tumor necrosis factor alpha has a protective role in a murine model of systemic candidiasis. Infect Immun (1994) 1.37
Release of tumor necrosis factor alpha and interleukin 6 during antibiotic killing of Escherichia coli in whole blood: influence of antibiotic class, antibiotic concentration, and presence of septic serum. Infect Immun (1995) 1.30
In vitro susceptibilities of Shigella flexneri and Streptococcus pyogenes to inner gel of Aloe barbadensis Miller. Antimicrob Agents Chemother (2003) 1.07
Differential release of smooth-type lipopolysaccharide from Pseudomonas aeruginosa treated with carbapenem antibiotics and its relation to production of tumor necrosis factor alpha and nitric oxide. Antimicrob Agents Chemother (1996) 0.94
Differential induction of pro- and anti-inflammatory cytokines in whole blood by bacteria: effects of antibiotic treatment. Antimicrob Agents Chemother (1997) 0.91
A protective role of platelet-activating factor in murine candidiasis. Infect Immun (1997) 0.87
Clindamycin suppresses endotoxin released by ceftazidime-treated Escherichia coli O55:B5 and subsequent production of tumor necrosis factor alpha and interleukin-1 beta. Antimicrob Agents Chemother (1999) 0.87
Comparable endotoxic properties of lipopolysaccharides are manifest in diverse clinical isolates of gram-negative bacteria. Infect Immun (2000) 0.82
Comparative effects of ciprofloxacin and ceftazidime on cytokine production in patients with severe sepsis caused by gram-negative bacteria. Antimicrob Agents Chemother (2004) 0.80
Influence of antibiotic and E5 monoclonal immunoglobulin M interactions on endotoxin release from Escherichia coli and Pseudomonas aeruginosa. Antimicrob Agents Chemother (1996) 0.78
G(AnH)MTetra, a naturally occurring 1,6-anhydro muramyl dipeptide, induces granulocyte colony-stimulating factor expression in human monocytes: a molecular analysis. Infect Immun (1994) 0.76
Oral administration of the anti-proliferative substance taurolidine has no impact on dextran sulfate sodium induced colitis-associated carcinogenesis in mice. J Carcinog (2010) 0.75
Endotoxin release and TNF production: a reappraisal. J Antimicrob Chemother (1993) 0.75
Clinical utility of C-reactive protein to predict treatment response during cystic fibrosis pulmonary exacerbations. PLoS One (2017) 0.75
The application of hematopoietic growth factors in drug-induced agranulocytosis: a review of 70 cases. Leukemia (1994) 2.26
Cytomegalovirus antigenemia. Rev Infect Dis (1990) 2.07
Association with HLA class I in Epstein-Barr-virus-positive and with HLA class III in Epstein-Barr-virus-negative Hodgkin's lymphoma. Lancet (2005) 2.03
The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia. Crit Rev Oncol Hematol (2004) 1.65
Infection prevention in granulocytopenic patients by selective decontamination of the digestive tract. Eur J Cancer (1980) 1.52
Constitutive Stat3, Tyr705, and Ser727 phosphorylation in acute myeloid leukemia cells caused by the autocrine secretion of interleukin-6. Blood (2000) 1.47
Coma with ECG abnormalities: consider tricyclic antidepressant intoxication. Neth J Med (2007) 1.47
Plasma IL-8 and IL-6 levels can be used to define a group with low risk of septicaemia among cancer patients with fever and neutropenia. Br J Haematol (1999) 1.46
[Meningitis after a superficial dog bite]. Ned Tijdschr Geneeskd (2002) 1.45
Effects of different types and combinations of antimicrobial agents on endotoxin release from gram-negative bacteria: an in-vitro and in-vivo study. Scand J Infect Dis (1991) 1.45
Autologous stem cell transplantation in multiple myeloma after VAD and EDAP courses: a high incidence of oligoclonal serum Igs post transplantation. Bone Marrow Transplant (2000) 1.42
Plasma levels of protein S, protein C, and factor X: effects of sex, hormonal state and age. Thromb Haemost (1995) 1.40
CD34+/CD36- cells from myelodysplasia patients have a limited capacity to proliferate but can differentiate in response to Epo and MGF stimulation. Leukemia (1998) 1.39
[An amebic liver abscess; early suspicion, late detection]. Ned Tijdschr Geneeskd (1997) 1.39
[Modern treatment methods for multiple myeloma: guidelines from the Dutch Haemato-Oncology Association (HOVON)]. Ned Tijdschr Geneeskd (2005) 1.38
Successful immunosuppressive treatment after failure of erythropoietin therapy in two subjects with refractory anaemia. Br J Haematol (1993) 1.38
[Hematopoietic growth factors as supportive treatment in drug-induced agranulocytosis]. Ned Tijdschr Geneeskd (1993) 1.38
Bacteriological aspects of selective decontamination of the digestive tract as a method of infection prevention in granulocytopenic patients. Antimicrob Agents Chemother (1981) 1.37
Ser727-dependent transcriptional activation by association of p300 with STAT3 upon IL-6 stimulation. FEBS Lett (2001) 1.36
A syndrome of liver damage and intravascular coagulation in the last trimester of normotensive pregnancy. A clinical and histopathological study. Br J Obstet Gynaecol (1986) 1.31
Determination of plasma protein S--the protein cofactor of activated protein C. Thromb Haemost (1985) 1.31
Lymphocyte-stimulation tests and patch tests to carbamazepine hypersensitivity. Clin Exp Immunol (1977) 1.26
Human granulocyte-monocyte colony-stimulating factor and interleukin 3 stimulate monocyte cytotoxicity through a tumor necrosis factor-dependent mechanism. Blood (1988) 1.26
Coagulation factor abnormalities as possible thrombotic risk factors after Fontan operations. Lancet (1990) 1.23
Regulation of constitutive STAT5 phosphorylation in acute myeloid leukemia blasts. Leukemia (2001) 1.23
Selective decontamination of the digestive tract with aztreonam: a study of 10 healthy volunteers. J Infect Dis (1984) 1.21
Recombinant human interleukin-6 induces a rapid and reversible anemia in cancer patients. Blood (1995) 1.19
Effects of recombinant human interleukin-6 in cancer patients: a phase I-II study. Blood (1994) 1.16
Proteases from Aspergillus fumigatus induce interleukin (IL)-6 and IL-8 production in airway epithelial cell lines by transcriptional mechanisms. J Infect Dis (1999) 1.16
Extracellular-regulated kinase 1/2, Jun N-terminal kinase, and c-Jun are involved in NF-kappa B-dependent IL-6 expression in human monocytes. J Immunol (1999) 1.16
IL-7 differentially modulates the expression of IFN-gamma and IL-4 in activated human T lymphocytes by transcriptional and post-transcriptional mechanisms. J Immunol (1996) 1.16
Therapeutic options in systemic AL amyloidosis. Neth J Med (2004) 1.12
Patterns of cytokines, plasma endotoxin, plasminogen activator inhibitor, and acute-phase proteins during the treatment of severe sepsis in humans. Crit Care Med (1992) 1.11
Multiple myeloma related cells in patients undergoing autologous peripheral blood stem cell transplantation. Br J Haematol (1999) 1.11
Class-specific antibody titres (ELISA) against the primary immunogen Helix pomatia haemocyanin (HPH) in man. Clin Exp Immunol (1978) 1.10
Platelet activation, fibrinolytic activity and circulating immune complexes in Raynaud's phenomenon. J Rheumatol (1983) 1.09
c-Jun and c-Fos cooperate with STAT3 in IL-6-induced transactivation of the IL-6 respone element (IRE). Cytokine (2001) 1.07
Expression of the macrophage colony-stimulating factor and c-fms genes in human acute myeloblastic leukemia cells. J Clin Invest (1988) 1.05
A familial hemorrhagic diathesis in a Dutch family: an inherited deficiency of alpha 2-antiplasmin. Blood (1982) 1.04
Anti-streptokinase antibodies inhibit fibrinolytic effects of anistreplase in acute myocardial infarction. Am J Cardiol (1993) 1.04
Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia. J Clin Oncol (1997) 1.04
Sequential activation of Rac-1, SEK-1/MKK-4, and protein kinase Cdelta is required for interleukin-6-induced STAT3 Ser-727 phosphorylation and transactivation. J Biol Chem (2001) 1.04
False-positive Paul-Bunnell test in HIV seroconversion. Lancet (1988) 1.04
MEN2A-RET-induced cellular transformation by activation of STAT3. Oncogene (2001) 1.03
Flare-up of rheumatoid arthritis during GM-CSF treatment after chemotherapy. Lancet (1991) 1.02
Constitutive NF-kappaB DNA-binding activity in AML is frequently mediated by a Ras/PI3-K/PKB-dependent pathway. Leukemia (2004) 1.02
Activity and expression of the multidrug resistance proteins MRP1 and MRP2 in acute myeloid leukemia cells, tumor cell lines, and normal hematopoietic CD34+ peripheral blood cells. Clin Cancer Res (1998) 1.02
Effects of IL-10 and IL-4 on LPS-induced transcription factors (AP-1, NF-IL6 and NF-kappa B) which are involved in IL-6 regulation. Leukemia (1996) 1.01
Secretion of interleukin-1 by acute myeloblastic leukemia cells in vitro induces endothelial cells to secrete colony stimulating factors. Blood (1987) 1.01
The p38 MAP kinase inhibitor SB203580 enhances nuclear factor-kappa B transcriptional activity by a non-specific effect upon the ERK pathway. Br J Pharmacol (2000) 0.99
Interleukin-6-induced STAT3 transactivation and Ser727 phosphorylation involves Vav, Rac-1 and the kinase SEK-1/MKK-4 as signal transduction components. Biochem J (2000) 0.99
Immunoglobulin and complement inclusions in peripheral blood polymorphonuclear leucocytes of patients with bronchial carcinoma. Thorax (1977) 0.99
Fusobacterium pyomyositis of the shoulder after tonsillitis. Report of a case of Lemierre's syndrome. Acta Orthop Scand (1991) 0.99
Signaling through CD5 activates a pathway involving phosphatidylinositol 3-kinase, Vav, and Rac1 in human mature T lymphocytes. Mol Cell Biol (1998) 0.98
The effects of GM-CSF and G-CSF in promoting growth of clonogenic cells in acute myeloblastic leukemia. Blood (1987) 0.98
Association of smooth muscle cell tissue factor with caveolae. Blood (1996) 0.97
MLL-AF9-mediated immortalization of human hematopoietic cells along different lineages changes during ontogeny. Leukemia (2012) 0.96
A case of localized Castleman's disease with systemic involvement: treatment and pathogenetic aspects. Ann Hematol (1996) 0.95
Increased bone marrow vascularization in patients with acute myeloid leukaemia: a possible role for vascular endothelial growth factor. Br J Haematol (2001) 0.95
Platelet kinetic studies in patients with idiopathic thrombocytopenic purpura. Am J Med (1999) 0.95
Gene expression profiling in the leukemic stem cell-enriched CD34+ fraction identifies target genes that predict prognosis in normal karyotype AML. Leukemia (2011) 0.95
A double-blind placebo-controlled study with granulocyte-macrophage colony-stimulating factor during chemotherapy for ovarian carcinoma. Cancer Res (1991) 0.95
Resistance of activated human Th2 cells to NO-induced apoptosis is mediated by gamma-glutamyltranspeptidase. Int Immunol (2001) 0.94
A dual function for p38 MAP kinase in hematopoietic cells: involvement in apoptosis and cell activation. Leukemia (1999) 0.94
Activity and expression of the multidrug resistance proteins P-glycoprotein, MRP1, MRP2, MRP3 and MRP5 in de novo and relapsed acute myeloid leukemia. Leukemia (2001) 0.94
Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma. Br J Haematol (1999) 0.93
Regulation of p100 (NFKB2) expression in human monocytes in response to inflammatory mediators and lymphokines. Leukemia (1998) 0.93
Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30% bone marrow blasts. Leuk Res (2013) 0.93
RFP2, c13ORF1, and FAM10A4 are the most likely tumor suppressor gene candidates for B-cell chronic lymphocytic leukemia. Cancer Genet Cytogenet (2003) 0.92
Homozygous alpha 2-antiplasmin deficiency. Lancet (1979) 0.92
Interleukin-4 inhibits the lipopolysaccharide-induced expression of c-jun and c-fos messenger RNA and activator protein-1 binding activity in human monocytes. Blood (1993) 0.92
Prostaglandin E2 differentially modulates IL-5 gene expression in activated human T lymphocytes depending on the costimulatory signal. J Allergy Clin Immunol (1998) 0.91
The influence of antibiotics on gut colonization. J Antimicrob Chemother (1986) 0.91
Adjuvant immunotherapy with BCG in squamous-cell bronchial carcinoma. Immune-reactivity in relation to immunostimulation (preliminary results in a controlled trial). Thorax (1978) 0.91
The effect of ceftriaxone on the anaerobic bacterial flora and the bacterial enzymatic activity in the intestinal tract. Infection (1992) 0.91
Regulation of spontaneous and TNF/IFN-induced IL-6 expression in two human ovarian-carcinoma cell lines. Int J Cancer (1999) 0.90
P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia. Clin Cancer Res (2000) 0.90
The influence of L-asparaginase therapy on the fibrinolytic system. Br J Haematol (1984) 0.90
Consensus strategy to quantitate malignant cells in myeloma patients is validated in a multicenter study. Belgium-Dutch Hematology-Oncology Group. Blood (2000) 0.90
Erythroid precursors from patients with low-risk myelodysplasia demonstrate ultrastructural features of enhanced autophagy of mitochondria. Leukemia (2009) 0.90
Basal tissue factor expression in endothelial cell cultures is caused by contaminating smooth muscle cells. Reduction by using chymotrypsin instead of collagenase. Thromb Res (1995) 0.89
A study of the cellular and humoral immune response in patients with myelofibrosis. Clin Lab Haematol (1982) 0.88
Consolidation therapy with autologous stem cell transplantation in plasma cell leukemia after VAD, high-dose cyclophosphamide and EDAP courses: a report of three cases and a review of the literature. Bone Marrow Transplant (1997) 0.88
Mobilized human CD34+ hematopoietic stem cells enhance tumor growth in a nonobese diabetic/severe combined immunodeficient mouse model of human non-Hodgkin's lymphoma. Cancer Res (2001) 0.88
The Ca2+/calmodulin-dependent kinase type IV is involved in the CD5-mediated signaling pathway in human T lymphocytes. J Biol Chem (1997) 0.88